Article info
PDFClinical and epidemiological research
Extended report
Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial
- Correspondence to Paul P Tak, AMC/University of Amsterdam, Clinical Immunology and Rheumatology, F4-105, PO Box 22700, Amsterdam 1100 DD, Netherlands; p.p.tak{at}amc.uva.nl
Citation
Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial
Publication history
- Accepted March 31, 2012
- First published May 15, 2012.
Online issue publication
April 12, 2023
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions